CN109641856A - 缬沙坦二钠盐的晶型 - Google Patents
缬沙坦二钠盐的晶型 Download PDFInfo
- Publication number
- CN109641856A CN109641856A CN201680088890.3A CN201680088890A CN109641856A CN 109641856 A CN109641856 A CN 109641856A CN 201680088890 A CN201680088890 A CN 201680088890A CN 109641856 A CN109641856 A CN 109641856A
- Authority
- CN
- China
- Prior art keywords
- crystal form
- disodium salt
- valsartan disodium
- salt crystal
- valsartan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
提供一类缬沙坦二钠盐的晶型A、B、D、E、F、G和H及其制备方法。
Description
PCT国内申请,说明书已公开。
Claims (26)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2016/097926 WO2018040065A1 (zh) | 2016-09-02 | 2016-09-02 | 缬沙坦二钠盐的晶型 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109641856A true CN109641856A (zh) | 2019-04-16 |
CN109641856B CN109641856B (zh) | 2022-09-30 |
Family
ID=61299687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201680088890.3A Active CN109641856B (zh) | 2016-09-02 | 2016-09-02 | 缬沙坦二钠盐的晶型 |
Country Status (4)
Country | Link |
---|---|
US (1) | US10745363B2 (zh) |
EP (1) | EP3508479A4 (zh) |
CN (1) | CN109641856B (zh) |
WO (1) | WO2018040065A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021111464A1 (en) * | 2019-12-02 | 2021-06-10 | Harman Finochem Limited | A process for the preparation of highly pure valsartan |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0443983A1 (de) * | 1990-02-19 | 1991-08-28 | Ciba-Geigy Ag | Acylverbindungen |
CN1443176A (zh) * | 2000-07-19 | 2003-09-17 | 诺瓦提斯公司 | 缬沙坦的盐 |
WO2008018843A1 (en) * | 2006-08-08 | 2008-02-14 | Ulkar Kimya Sanayi Ve Ticaret As | Process for producing useful salts form of biphenyl-tetrazole compounds |
CN102596899A (zh) * | 2009-10-27 | 2012-07-18 | 诺瓦提斯公司 | 制备有机化合物的方法 |
CN102702119A (zh) * | 2005-11-09 | 2012-10-03 | 诺瓦提斯公司 | 血管紧张素受体拮抗剂和nep抑制剂的药物组合产品 |
WO2016074651A1 (en) * | 2014-11-14 | 2016-05-19 | Zentiva, K.S. | A method for the preparation, isolation and purification of pharmaceutically applicable forms of ahu-377 |
WO2016125123A1 (en) * | 2015-02-06 | 2016-08-11 | Mylan Laboratories Limited | Amorphous trisodium sacubitril valsartan and a process for the preparation thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN201813039U (zh) | 2010-10-18 | 2011-04-27 | 重庆长安汽车股份有限公司 | 一种汽车线束连接器卡扣 |
KR102254062B1 (ko) * | 2015-06-12 | 2021-05-20 | 테바 파마슈티컬스 인터내셔널 게엠베하 | 삼나트륨 발사르탄:사쿠비트릴의 고체 형태 |
EP3117823A1 (en) * | 2015-07-17 | 2017-01-18 | Quimica Sintetica, S.A. | Amorphous solid dispersion comprising an angiotensin receptor blocker and a neutral endopeptidase inhibitor |
WO2019020706A1 (en) * | 2017-07-28 | 2019-01-31 | Synthon B.V. | PHARMACEUTICAL COMPOSITION COMPRISING SACUBITRIL AND VALSARTAN |
-
2016
- 2016-09-02 WO PCT/CN2016/097926 patent/WO2018040065A1/zh unknown
- 2016-09-02 CN CN201680088890.3A patent/CN109641856B/zh active Active
- 2016-09-02 EP EP16914631.3A patent/EP3508479A4/en not_active Withdrawn
- 2016-09-02 US US16/329,992 patent/US10745363B2/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0443983A1 (de) * | 1990-02-19 | 1991-08-28 | Ciba-Geigy Ag | Acylverbindungen |
CN1443176A (zh) * | 2000-07-19 | 2003-09-17 | 诺瓦提斯公司 | 缬沙坦的盐 |
CN102702119A (zh) * | 2005-11-09 | 2012-10-03 | 诺瓦提斯公司 | 血管紧张素受体拮抗剂和nep抑制剂的药物组合产品 |
WO2008018843A1 (en) * | 2006-08-08 | 2008-02-14 | Ulkar Kimya Sanayi Ve Ticaret As | Process for producing useful salts form of biphenyl-tetrazole compounds |
CN102596899A (zh) * | 2009-10-27 | 2012-07-18 | 诺瓦提斯公司 | 制备有机化合物的方法 |
WO2016074651A1 (en) * | 2014-11-14 | 2016-05-19 | Zentiva, K.S. | A method for the preparation, isolation and purification of pharmaceutically applicable forms of ahu-377 |
WO2016125123A1 (en) * | 2015-02-06 | 2016-08-11 | Mylan Laboratories Limited | Amorphous trisodium sacubitril valsartan and a process for the preparation thereof |
Also Published As
Publication number | Publication date |
---|---|
US10745363B2 (en) | 2020-08-18 |
EP3508479A4 (en) | 2020-02-19 |
EP3508479A1 (en) | 2019-07-10 |
WO2018040065A1 (zh) | 2018-03-08 |
CN109641856B (zh) | 2022-09-30 |
US20190194149A1 (en) | 2019-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113527203B (zh) | 乐伐替尼甲磺酸盐的晶型及其制备方法和用途 | |
CA2746652C (en) | Crystalline forms of genistein | |
CN106420743A (zh) | C‑met调节剂药物组合物 | |
CN105085517B (zh) | 一种结晶型帕博西尼游离碱水合物及其制备方法 | |
JP6752822B2 (ja) | キナゾリンクロチル化合物二マレイン酸塩結晶、ならびに、その調製方法および使用 | |
CN109641856A (zh) | 缬沙坦二钠盐的晶型 | |
CN104478815A (zh) | 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1,2,4-三唑-3-基硫基)乙酸的多种盐、它们的晶型及其制备方法 | |
US7863325B2 (en) | Crystalline genistein sodium salt dihydrate | |
CN115385893A (zh) | 与吡啶酰基哌啶5-ht1f激动剂相关的组合物和方法 | |
CN105085476B (zh) | 5‑[2,6‑二(4‑吗啉基)‑4‑嘧啶基]‑4‑(三氟甲基)‑2‑吡啶胺二盐酸盐的晶型及其制备方法 | |
AU2019334693A1 (en) | Novel hydrochloride salt forms of a sulfonamide structured kinase inhibitor | |
TWI648267B (zh) | 纈沙坦二鈉鹽新晶型 | |
CN109232582A (zh) | 拉洛替尼硫酸氢盐晶型及其制备和应用 | |
JP2022511947A (ja) | 1-[(3r,4s)-4-シアノテトラヒドロピラン-3-イル]-3-[(2-フルオロ-6-メトキシ-4-ピリジル)アミノ]ピラゾール-4-カルボキサミドの結晶形態 | |
WO2022171117A1 (zh) | 含氮稠杂环化合物的盐、晶型及其制备方法、药物组合物和用途 | |
CN109661386A (zh) | 沙库比曲钠盐新晶型 | |
JP2023545165A (ja) | 多置換ベンゼン環化合物マレイン酸塩の結晶形、その調製方法及びその用途 | |
CN108699007A (zh) | 氟班色林的新晶型及其制备方法及其用途 | |
CN104961688A (zh) | 一种表皮生长因子受体激酶抑制剂的磷酸盐及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20191224 Address after: 6 / F, building F6, No.9, Weidi Road, Jiangsu life science and Technology Innovation Park, Qixia District, Nanjing City, Jiangsu Province Applicant after: NANJING NORATECH PHARMACEUTICALS Co.,Ltd. Address before: Taipei City, Taiwan, China Applicant before: NORATECH PHARMACEUTICALS, Inc. |
|
GR01 | Patent grant | ||
GR01 | Patent grant |